A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease Dementia

• Status: Recruiting
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease dementia.

The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease dementia treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease dementia treated with KarXT compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karuna Therapeutics

Criteria

Inclusion Criteria:

1. Is aged 55 to 90 years, inclusive, at Screening

2. Can understand the nature of the study and protocol requirements and provide a signed informed consent form before any study assessments are performed. If the subject is deemed not competent to provide consent, the following requirements for consent must be met.

1. The subject's legally acceptable representative or caregiver/study partner, if local regulations allow, must provide informed consent

2. The subject must provide informed assent

3. Meets clinical criteria for possible or probable Alzheimer's Disease

4. Has a Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome. If not available, a non-contrast brain MRI or non-contrast head CT must be done during screening.

5. Living at the same home or residential assisted-living facility for a minimum of six weeks before Screening

6. Capable of self-locomotion (alone or with the aid of an assistive device) and have an identified or proxy caregiver (spends approximately 10 hours/week with the subject) that is willing to:

1. Attend all visits and report on subject's status

2. Oversee subject compliance with medication and study procedures

3. Participate in the study assessments and provide informed consent to participate in the study

7. History of psychotic symptoms (meeting International Psychogeriatric Association [IPA] criteria) for at least 2 months prior to Screening.

8. Clinical Global Impressions-Severity (CGI-S) scale with a score ≥4 (moderate) at Screening (Visit 1A). CGI-S requires the assessor to consider aspects of the psychosis prior to providing a global assessment of severity. These aspects include hallucinations and delusions.

9. Subjects are required to meet at least one of the following criteria at Screening:

1. Moderate to severe delusions, defined as Neuropsychiatric Inventory-Clinician (NPI-C): Delusions domain score of ≥2 on two of the eight items OR

2. Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on two of the seven items.

10. Mini-Mental State Examination (MMSE) score of 8 to 22, inclusive, at Screening

11. If the subject is taking a cholinesterase inhibitor and/or memantine, they must have been on a stable dose for 6 weeks prior to Screening and be willing to maintain a stable dose for the duration of the study.

12. Subject is willing and able to visit the clinic in an outpatient setting for the study duration, follow instructions, and comply with the protocol requirements

13. BMI must be within 18 to 40 kg/m2

14. Female subjects must not be pregnant or breastfeeding. Women of childbearing potential (WOCBP), or men whose sexual partners are WOCBP, must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of IMP or matching placebo. Sperm donation is not allowed for 30 days after the final dose of the IMP or matching placebo.

Exclusion Criteria:

1. Psychotic symptoms that are primarily attributable to a condition other than the Alzheimer's Disease causing dementia e.g., schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features

2. History of major depressive episode with psychotic features during the 12 months prior to Screening

3. History of an axis I diagnosis of delirium, amnestic disorder, bipolar disorder, schizophrenia, or schizoaffective disorder

4. Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results

5. History of ischemic stroke within 12 months prior to Screening or any evidence of hemorrhagic stroke

6. History of cerebral amyloid angiopathy, epilepsy, central nervous system neoplasm, unstable thyroid function, or unexplained syncope

7. Any of the following:

1. New York Heart Association Class 2 congestive heart failure

2. Grade 2 or greater angina pectoris

3. Sustained ventricular tachycardia

4. Ventricular fibrillation

5. Torsade de pointes

6. Implantable cardiac defibrillator

8. Myocardial infarction within the 6 months prior to Screening

9. Personal or family history of symptoms of long QT syndrome as evaluated by the investigator

10. Human immunodeficiency virus, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections as indicated by medical history or liver function tests results

11. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the investigator

12. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months

13. Risk of suicidal behavior during the study as determined by clinical assessment and/ or C-SSRS

14. Clinically significant abnormal finding on the physical examination, medical history, electrocardiogram, or clinical laboratory results at Screening

15. Urine toxicology screen is positive for non-cannabis or non-benzodiazepine substances without the approval of the Medical Monitor

16. Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (e.g., lamotrigine, divalproex), lithium, tricyclic antidepressants (e.g., imipramine, desipramine), or any other psychoactive medications except for as-needed anxiolytics (e.g., lorazepam, chloral hydrate)

1. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening may be permitted

2. Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening If needed, an extension (up to two weeks) of the Screening Period may be allowed with approval of the Sponsor/Medical Monitor.

17. If, in the opinion of the Investigator and/or Sponsor/Medical Monitor, subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator and/or Sponsor/ Medical Monitor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements

18. Positive test for coronavirus (COVID-19) within 2 weeks before or at Screening

19. Unable to taper and discontinue a concomitant medication that would preclude participation in the study

20. Prior exposure to KarXT

21. Experienced any significant adverse events due to trospium

22. Participation in another clinical study in which the subject received an experimental or investigational drug within 3 months before Screening or has participated in more than 2 clinical studies in the past year